Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.83−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $133.03MP/E –Yield –
Moleculin Biotech operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Moleculin Biotech's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.36M. For fiscal 2025 it was -$22.74M. The highest annual figure on record is -$3.77M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.74M | – |
| FY2024 | Dec 31, 2024 | -$23.86M | – |
| FY2023 | Dec 31, 2023 | -$23.59M | – |
| FY2022 | Dec 31, 2022 | -$27.64M | – |
| FY2021 | Dec 31, 2021 | -$18.95M | – |
| FY2020 | Dec 31, 2020 | -$17.77M | – |
| FY2019 | Dec 31, 2019 | -$17.20M | – |
| FY2018 | Dec 31, 2018 | -$12.20M | – |
| FY2017 | Dec 31, 2017 | -$7.32M | – |
| FY2016 | Dec 31, 2016 | -$3.77M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.22M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.58M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.02M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.26M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.62M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.37M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.93M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.33M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.85M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.39M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.61M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.17M | – |
| Q3 FY2016 | Sep 30, 2016 | -$951.00K | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.36M | – |
See a number that looks wrong?